Seqens adds to US R&D lab
21st March 2022
Submitted by:
Andrew Warmington
CDMO and API manufacturer Seqens has announced a “multi-million dollar” investment in its R&D laboratory in Devens, Massachusetts, which is due to be completed in October. The firm said that this will ensure that the new facility can operate at the highest standards of safety and quality.
This comes three months after SK Capital became a majority holder in Seqens by merging it with its existing portfolio company Wavelength Pharmaceuticals. The company is making further investments around the world. In the US, it also has a CDMO operation in Newburyport, Massachusetts, which was formerly PCI Synthesis.